Chief Executive Officer, Jupiter Bioventures

Over the past 22 years, Ned has co-founded four biotechnology companies that have collectively raised over $2 billion in financing and have given rise to three IPOs, two M&A acquisitions, and four FDA-approved medicines (ALOGLIPTIN, TRELAGLIPTIN, ZEMDRI, and KYBELLA). Ned cofounded Syrrx (acquired by Takeda), Achaogen (NASDAQ: AKAO), Kythera Biopharmaceuticals (NASDAQ: KYTH, acquired by Allergan), and UNITY Biotechnology (NASDAQ: UBX). Ned holds 46 allowed patents in fields as far flung as nanovolume crystallography, antibiotic resistance, aesthetic medicine, and cellular senescence. Ned has served on the board of directors of Kythera Biopharmaceuticals, UNITY Biotechnology, the Buck Institute for Research on Aging and is a member of the board of trustees of the University of California Foundation. Ned was named one of the Top 100 innovators in the world by the MIT Technology Review and received the Honorary Leadership Award from the American Federation for Research on Aging (AFAR). He holds a Ph.D. from the University of California, Berkeley in Molecular and Cellular Biology and an A.B. in Biology from Harvard.